Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir

Journal of Clinical Virology

Volumn 72, Issue , 2015, Pages 133-140

  Fevery, Bart ^a   Susser, Simone ^b   Lenz, Oliver ^a   Cloherty, Gavin ^c   Perner, Dany ^b   Gilles, Leen ^a   De Locht, Patrick ^a   Picchio, Gaston ^d   De Meyer, Sandra ^a   Sarrazin, Christoph ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b GOETHE UNIVERSITY   (Germany)

^c Abbott Molecular Inc   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Assay concordance; DAA; HCV genotype 1 and 4; HCV RNA quantification; Response guided treatment; Simeprevir

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ANALYZER; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA ANALYSIS; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; DRUG MONITORING; EVALUATION STUDY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; PROCEDURES; RETROSPECTIVE STUDY; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG MONITORING; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SIMEPREVIR; VIRAL LOAD;

EID: 84946413425     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.09.015     Document Type: Article

References (18)

1. Feeney E.R., Chung R.T. Antiviral treatment of hepatitis C. BMJ 2014, 348:g3308.
2. Ansaldi F., Orsi A., Sticchi L., Bruzzone B., Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J. Gastroenterol. 2014, 20:9633-9652.
3. Colucci G., Ferguson J., Harkleroad C., Lee S., Romo D., Soviero S., et al. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J. Clin. Microbiol. 2007, 45:3595-3600.
4. Vermehren J., Yu M.L., Monto A., Yao J.D., Anderson C., Bertuzis R., et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J. Clin. Virol. 2011, 52:133-137.
5. Zitzer H., Heilek G., Truchon K., Susser S., Vermehren J., Sizmann D., et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J. Clin. Microbiol. 2013, 51:571-577.
6. Abbott Molecular Inc, Package insert. Abbott RealTime HCV, (accessed 8.1.15.). http://www.abbottmolecular.com/static/cms_workspace/pdfs/US/Abbott_RealTime_HCV_PI.pdf.
7. Roche Molecular Systems, COBAS® TaqMan® HCV Test, v2.0 product information, (accessed 8.1.15.). http://molecular.roche.com/assays/Pages/COBASTaqManHCVTestv20HPS.aspx.
8. Roche Molecular Systems, COBAS® AmpliPrep/COBAS® TaqMan® HCV Qualitative Test, v2.0, aspx (accessed 8.1.15). http://molecular.roche.com/assays/Pages/COBASAmpliPrepCOBASTaqManHCVQualTest_v2.aspx.
9. Fevery B., Susser S., Lenz O., Cloherty G., Perner D., Picchio G., et al. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy. Antivir. Ther. 2014, 19:559-567.
10. Taylor N., Haschke-Becher E., Greil R., Strasser M., Oberkofler H. Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections. Antivir. Ther. 2014, 19:449-454.
11. Cloherty G., Cohen D., Sarrazin C., Wedemeyer H., Chevaliez S., Herman C., et al. HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. Antivir. Ther. 2015, 20:177-183.
12. Sarrazin C., Dierynck I., Cloherty G., Ghys A., Janssen K., Luo D., et al. An OPTIMIZE Study retrospective analysis for the management of telaprevir-treated HCV patients using the Abbott RealTime HCV RNA assay. J. Clin. Microbiol. 2015, 53:1264-1269.
13. Vermehren J., Aghemo A., Falconer K., Susser S., Lunghi G., Zeuzem S., et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J. Hepatol. 2014, 60:913-919.
14. Janssen Research & Development, Olysio™ (simeprevir) US Prescribing Information, (accessed 11.2014). http://www.olysio.com/shared/product/olysio/prescribing-information.pdf.
15. Jacobson I.M., Dore G.J., Foster G.R., Fried M.W., Radu M., Rafalsky V.V., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014, 384:403-413. 10.1016/s0140-6736(14)60494-3.
16. Manns M., Marcellin P., Poordad F., de Araujo E.S., Buti M., Horsmans Y., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014, 384:414-426. 10.1016/s0140-6736(14)60538-9.
17. Moreno C., Hezode C., Marcellin P., Bourgeois S., Francque S., Samuel D., et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J. Hepatol. 2015, 62:1047-1055. 10.1016/j.jhep.2014.12.031.
18. Vermehren J., Maasoumy B., Chevaliez S., Feld J.J., Cloherty G., Pawlotsky J.M., et al. Assessment of baseline viral load cut-off for shortened ledipasvir/sofosbuvir therapy by widely used HCV RNA assays. J. Hepatol. 2015, 62:S263.